Irene Ghobrial, MD receives SU2C Catalyst grant
Irene Ghobrial, MD, co-director of the Center for Prevention of Progression of Blood Cancers, is among the first to receive a research...
top of page
PCROWD NEWS
Search
Early treatment may prevent progression to multiple myeloma
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk “smoldering” multiple myeloma to the...
Monoclonal gammopathy of unknown significance (MGUS) & importance of regularly monitoring patients
Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses monoclonal gammopathy of unknown significance (MGUS). There...
How to use social media in clinical trials - reaching out to patients
Irene Ghobrial, MD of Dana-Farber Cancer Institute, Boston, MA, discusses ways to use social media in clinical trials. +watch video
Benefits of early therapeutic intervention for high-risk smouldering multiple myeloma patients
Irene Ghobrial, MD of Dana-Farber Cancer Institute, Boston, MA, discusses the benefits of early therapeutic interventions for patients...
How can we improve our understanding of the progression of myeloma?
Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), Boston, MA, discusses the progression of multiple myeloma (MM), which...
The genomics behind blood cancers and other blood disorders
Many of the secrets of why precancerous conditions sometimes become cancerous are hidden in cells’ genes. At Dana-Farber, researchers are...
Precursor Blood Condition Patient Pays it Forward
When Lori Kauzlarich discovered that she had a precursor blood condition in August 2013, she sprang into action. +read more .
How I Treat Smoldering Multiple Myeloma - Irene M. Ghobrial
Dr. Ghobrial discusses smoldering myeloma, a heterogeneous clinical entity where some patients have a very indolent course of disease...
Treatment is Waiting
In 2014, Ghobrial launched Dana-Farber’s new Center for Prevention of Progression of Blood Cancers, which sees patients with early...
Gift funds precursor condition research for blood cancers
A generous gift from anonymous donors may give new hope to those diagnosed with “precursor conditions,” conditions that, although not yet...
Preventing Myeloma Before it Gets Started with Dr. Irene Ghobrial, MD, Dana-Farber Cancer Institute
Interview with the Myeloma Crowd Radio - Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene...
Irene Ghobrial, MD, explains Dana-Farber's CPOP
Irene Ghobrial, MD, explains the strategy and need for Dana-Farber’s Center for the Prevention of Progression of Blood Cancers -- a...
Why do Waldenström Macroglobulinemia and Multiple Myeloma change from MGUS to active disease?
In this presentation, Dr. Irene M. Ghobrial discusses why MGUS changes to active disease. +watch video
Myeloma Crowd: Now Enrolling for PCROWD study: Patients with precursor conditions such as MGUS & Smo
Most blood cancers are preceded by clonal disease states that then progress into disease. However, the genomic, genetic, and epigenetic...
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Recent genetic analyses of large populations have revealed that somatic mutations in hematopoietic cells leading to clonal expansion are...
New Clinic Focuses on Why Some Conditions Become Cancer While Others Don't
Thousands of people learn each year - usually after a routine blood test - that they have a condition that may develop into a blood...
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and C
Bulletin overview of “Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression...
bottom of page